Table 3.
Physician assessment of the effectiveness and tolerability of ivabradine after 4 months in the ADDITIONS population, according to PCI status
| Ivabradine | Patients with previous PCI (n = 1,193) | Patients with no previous PCI (n = 1,126) |
|---|---|---|
| Effectiveness | 1,170 (98%) | 1,109 (98%) |
| Very good | 732 (63%) | 662 (60%) |
| Good | 412 (35%) | 409 (37%) |
| Moderate | 25 (2%) | 36 (3%) |
| Bad | 1 (< 1%) | 2 (< 1%) |
| Tolerability | 1,136 (95%) | 1,065 (95%) |
| Very good | 805 (71%) | 768 (72%) |
| Good | 328 (29%) | 295 (28%) |
| Moderate | 2 (< 1%) | 2 (< 1%) |
| Bad | 1 (< 1%) | 0 (0%) |
Values are patient numbers and percentages (%)
PCI percutaneous coronary intervention